相关实验视频

Updated: Jul 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

管理KRAS突变非小细胞肺癌的管理

Jyoti Malhotra^1,2, Danny Nguyen^1,2, Tingting Tan^1,2

¹City of Hope Orange County, Irvine, California.

Clinical advances in hematology & oncology : H&O

|March 6, 2024

概括

针对基尔斯大鼠肉瘤病毒 (KRAS) G12C突变非小细胞肺癌 (NSCLC) 的向疗法已经得到了先进的治疗. 然而,耐药性机制需要新的组合策略和个性化治疗KRAS突变NSCLC.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

基尔斯鼠肉瘤病毒 (KRAS) 是人类癌症中经常发生突变的瘤基因,特别是非小细胞肺癌 (NSCLC).
克拉斯G12C是最常见的克拉斯变体,在很大一部分NSCLC病例中推动瘤生长.
从历史上看,KRAS被认为是无法治疗的,直到选择性KRAS G12C抑制剂的开发.

研究的目的:

审查KRAS G12C抑制剂在晚期或转移性NSCLC中的当前情况.
讨论对KRAS G12C抑制剂耐药性的机制.
突出新治疗策略的发展,包括下一代抑制剂和组合疗法,用于KRAS突变NSCLC.

主要方法:

关于KRAS G12C抑制剂的最近临床试验和研究的文献综述.
对针对性KRAS G12C疗法的耐药性机制的分析.
对正在进行的新型治疗方法早期试验的概述.

主要成果:

选择性KRAS G12C抑制剂如索托拉西布和阿达格拉西布已经改变了高级NSCLC的护理标准.
对KRAS G12C抑制剂的耐药性是异质的,涉及到目标,非目标和形态切换机制.
这些抗药性机制限制了单一治疗的有效性,推动了对替代策略的需求.

结论:

新一代抑制剂和组合策略正在开发中,以克服或延迟耐药性.
个性化治疗方法,考虑到同时发生的突变和生物异质性,对于管理KRAS突变NSCLC至关重要.
针对非G12C KRAS突变也是一个活跃的研究领域.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...